The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates at the intersection of consumer health, wellness and digital healthcare, blending telemedicine, personalized treatments and direct-to-consumer wellness products into a unified model. Its platform provides access to licensed healthcare professionals and personalized care plans for chronic and lifestyle conditions such as sexual health, hair loss, dermatology, mental health and weight management. This model integrates telehealth consultations, pharmacy fulfillment and recurring subscriptions -- creating a recurring revenue stream while enabling precision-based, individualized care.
The company's business model overlaps in consumer health and wellness stems from its emphasis on accessibility and personalization. Hims & Hers' growth strategy expands beyond digital prescriptions into holistic care, supported by its acquisition of Trybe Labs for lab testing and MedisourceRx for compounding capabilities. This vertical integration enhances its precision health infrastructure. The recent appointment of AI expert Mo Elshenawy as chief technology officer (CTO) and an $870 million convertible note offering underscore its ambition to scale AI-driven diagnostics and treatments globally.
Recent category launches further broaden its consumer health portfolio. The introduction of a men's oral testosterone line and women's menopause and perimenopause specialty marks major entries into hormonal health, complementing the company's expanding weight loss offerings. Coupled with its ZAVA acquisition in Europe and planned 2026 expansion to Canada, Hims & Hers is evolving into a global, technology-enabled consumer wellness provider that combines medical-grade treatment access with personalized lifestyle care.
GoodRx Holdings, Inc. GDRX operates at the intersection of healthcare, technology and consumer wellness, connecting patients, pharmacies and drug manufacturers through its digital savings platform. In October, GDRX introduced GoodRx for Hair Loss, a men's subscription offering virtual consultations and affordable treatments, and RxSmartSaver, a pharmacy-counter program expanding savings on brand drugs. Its collaboration with Amgen on Repatha further emphasizes GoodRx's role in expanding affordable access and strengthening its position in the consumer health and wellness ecosystem.
Medifast, Inc. MED is shifting from weight loss to metabolic health, introducing Metabolic Synchronization, which resets metabolism to reduce visceral fat and preserve lean mass. Supported by research on its Optimal Weight 5 & 1 Plan, showing 98% lean mass preservation, Medifast leverages clinical science, personalized coaching and behavioral support to enhance metabolic outcomes. Medifast's evidence-based, coach-guided approach aligns it with the broader consumer health and wellness movement focused on longevity and vitality.
HIMS' forward 12-month P/S of 3.7X is lower than the industry's average of 5.6X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 118.5% improvement from 2024.
MEDIFAST INC (MED) : Free Stock Analysis Report
GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).